Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln

México Noticias Noticias

Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln
México Últimas Noticias,México Titulares
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 97%

Royalty Pharma Plc undefined said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. undefined. The...

Royalty Pharma Plc said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. . The royalties include Ionis' interests in Biogen's Spinraza medicine and Novartis' pelacarsen. Shares of Royalty Pharma rose 1.9% in premarket trades while Ionis rose 2.6%.

... Royalty Pharma Plc RPRX said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. IONS . The royalties include Ionis' interests in Biogen's BIIB Spinraza medicine and Novartis' NVS pelacarsen. Shares of Royalty Pharma rose 1.9% in premarket trades while Ionis rose 2.6%.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

MarketWatch /  🏆 3. in US

México Últimas Noticias, México Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealAstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealAstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
Leer más »

Breakingviews - AstraZeneca’s new deal is smarter than it looksBreakingviews - AstraZeneca’s new deal is smarter than it looksOn the face of it, Pascal Soriot’s new deal ought to raise his shareholders’ blood pressure. The boss of $221 billion pharma giant AstraZeneca has agreed to buy CinCor Pharma for up to $1.8 billion. Yet paying $26 in cash per CinCor share and an extra $10 per share if a key drug is submitted for regulatory approval represents a 206% bump to CinCor’s closing share price on Friday. That’s around four times the average premium on recent industry deals.
Leer más »

AstraZeneca PLC Will Buy CinCor for Cardiorenal AssetAstraZeneca PLC Will Buy CinCor for Cardiorenal AssetBy Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug...
Leer más »

AstraZeneca boosts heart, kidney business with $1.8 bln CinCor dealAstraZeneca boosts heart, kidney business with $1.8 bln CinCor dealAstraZeneca said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc for up to $1.8 billion to increase its stock of heart and kidney drugs.
Leer más »

Report: Saints, Michael Thomas Agree to Restructured ContractReport: Saints, Michael Thomas Agree to Restructured ContractThe Saints and wide receiver Michael Thomas agreed to a restructured contract that creates a potential deadline for the team to decide whether to bring him back next year
Leer más »

Indonesia and Malaysia agree to fight 'discrimination' against palm oilIndonesia and Malaysia agree to fight 'discrimination' against palm oilIndonesia and Malaysia, the world's biggest producers of palm oil, agreed on Monday to work together to fight 'discrimination' against the commodity after a meeting between leaders from the countries.
Leer más »



Render Time: 2025-02-28 20:39:40